Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination "azathioprine + calcitriol + methylprednisolone" represents a multi-drug regimen rather than a single branded combination product. Each component has distinct mechanisms of action and uses, though they may be prescribed together in certain clinical scenarios. ## Azathioprine Azathioprine is an immunosuppressant prodrug of 6-mercaptopurine, first synthesized in 1956 by Gertrude Elion, William Lange, and George Hitchings[3]. It's used to treat inflammatory conditions like rheumatoid arthritis and as an immunosuppressant in the prevention of renal transplant rejection[3]. Azathioprine received FDA approval on March 20, 1968[3]. ## Methylprednisolone Methylprednisolone is a corticosteroid used to treat inflammation or immune reactions across various organ systems[1]. Its primary use is to suppress inflammatory and immune responses by regulating the number and function of leukocytes, cytokines, and chemokines[7]. It's commonly prescribed as short-term therapy for acute flares, such as in acute gouty arthritis[7]. ## Combination Use The combination of azathioprine and corticosteroids (like methylprednisolone) has been studied in various conditions: 1. **Rheumatoid Arthritis**: Methylprednisolone pulse therapy in conjunction with azathioprine has shown a short-lasting beneficial effect in persistently active rheumatoid arthritis[2]. 2. **Serpiginous Choroiditis**: When azathioprine is used in combination with corticosteroids, it has been found to be a safe and acceptable option for treating patients with active serpiginous choroiditis[5]. 3. **Renal Transplantation**: Azathioprine was initially used in combination with prednisolone as 'double therapy' for renal transplantation[6]. 4. **Lupus Nephritis**: In severe manifestations of Systemic Lupus Erythematosus, patients are often prescribed methylprednisolone concomitantly with immunosuppressants, and maintenance therapy may include oral prednisolone and azathioprine[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Azathioprine + Calcitriol + Methylprednisolone.